Analyses of the urinary and gut microbiomes and a quality improvement to standardize use of antibiotics after prostate biopsy were among other AUA 2016 highlights in this therapeutic area.
Christina B. Ching, MDAnalyses of the urinary and gut microbiomes and a quality improvement to standardize use of antibiotics after prostate biopsy were among AUA 2016 highlights in this therapeutic area. The infection/inflammation take-home messages were presented by Christina B. Ching, MD, of Nationwide Children's Hospital, Columbus, OH.
An examination of urine showed increased toxic urinary cations in males with interstitial cystitis (IC), providing potential mechanistic insight for the cause of IC/bladder pain syndrome.
Differential expression of a multi-marker panel of chemokines can distinguish between normal and decreased bladder capacity in IC patients. The finding could allow for phenotypic characterization of IC using a biomarker.
In a study involving a new class of agents for the treatment of IC known as SHIP activators, AQX-1125 decreased visceral pain and bladder inflammation in a rat model. Also, a randomized, double-blind, placebo-controlled phase II trial showed SHIP-1 activation provides significantly improved pain scores and scores on standardized questionnaires.
Agents that improve abdominal pain may be able to improve urologic symptoms through common sensory innervation pathways.
The urinary microbiome differs significantly between patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and controls as well as between patients with different clinical phenotypes, with the urinary microbiome in CP/CPPS patients having significantly increased alpha diversity. An analysis of the gut microbiome also revealed significant difference between men with CP/CPPS and controls, with the gut microbiome in CP/CPPS patients having significantly decreased alpha diversity.
Continue to the next page for more take-home messages.
Next: Transurethral catheterization, suprapubic tube, and CIC compared
Stone Disease: New AUA guide discusses SWL vs. URS
Prostate Ca: PSA drop, active surveillance are key themes
Infertility/Andrology: Are vasectomy and prostate Ca linked?
Subscribe to Urology Times to get monthly news from the leading news source for urologists.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.